Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

Xience Prime Orsiro Drug Eluting Stent BIO-GLOW II Clinical Study Biotronik Abbo
News | July 01, 2013

July 1, 2013 — Primary end-point results from the BIOFLOW-II...

News | June 24, 2013

June 24, 2013 — Final six and 12-month results of the DIRECT first-in-man...

News | June 11, 2013

June 11, 2013 — New long-term data from the DIVERGE...

Xience Xpedition 48 Abbott Vascular CE mark Europe
News | May 28, 2013

May 28, 2013 — Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent...

News | April 30, 2013

April 30, 2013 — Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral...

Medtronic Resolute Drug Eluting Stent Dual Antiplatelet Therapy Clinical
News | March 28, 2013

March 28, 2013 — Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute...

News | March 20, 2013

March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct...

News | February 28, 2013

February 28, 2013 — OrbusNeich announced that OrbusNeich Medical GmbH has commenced patent infringement actions in...

Medtronic Resolute Integrity Stent FDA Approval 34, 38 mm
Technology | February 25, 2013

February 25, 2013 — The U.S. Food and Drug Administration (FDA) has approved the 34 and 38 mm lengths of the...

Feature | February 18, 2013

February 18, 2013 — Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum...

Biosensors BioMatrix

The LEADERS Trial showed that the Biosensors BioMatrix, a drug-eluting stent with a biodegradable abluminal polymer coating, was functionally equivalent to a regular nonbiodegradable stent.

Feature | February 04, 2013 | Kamran Zamanian, Ph.D.

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents,...

BioSensors International BioFreedom Drug Coated Stent CE mark
News | January 31, 2013

January 31, 2013 — Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (...

Feature | January 16, 2013

January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-...

Abbott Absorb bioresorbable stent
Feature | January 08, 2013

January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States...

News | January 07, 2013

January 7, 2013 — Biosensors International has announced enrollment of the first patient in LEADERS FREE, a...

Overlay Init